anastrozole has been researched along with Pain in 12 studies
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer." | 9.19 | Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. ( Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B, 2014) |
| "To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning." | 9.11 | Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. ( Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F, 2005) |
| "A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain." | 9.11 | Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. ( Gallo, J; Morris, T; Saltzstein, D; Sieber, P, 2005) |
| "A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life." | 9.11 | Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. ( Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A, 2005) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer." | 5.19 | Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. ( Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B, 2014) |
| "To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning." | 5.11 | Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. ( Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F, 2005) |
| "A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain." | 5.11 | Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. ( Gallo, J; Morris, T; Saltzstein, D; Sieber, P, 2005) |
| "A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life." | 5.11 | Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. ( Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A, 2005) |
| "Use of aromatase inhibitors (AIs), exemestane, letrozole and anastrozole, for breast cancer therapy is associated with severe pain symptoms, the underlying mechanism of which is unknown." | 3.80 | Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1. ( Benemei, S; Coppi, E; De Logu, F; Di Tommaso, MR; Fusi, C; Geppetti, P; Marone, IM; Materazzi, S; Minocci, D; Moneti, G; Nassini, R; Pieraccini, G; Susini, T; Trevisan, G; Tuccinardi, T, 2014) |
| "Patients with early breast cancer and AIMSS were stratified according to their baseline 25-hydroxy vitamin D (25OHD) level." | 2.76 | Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. ( Armamento-Villareal, R; Ellis, MJ; Gao, F; Jamalabadi-Majidi, S; Napoli, N; Rastelli, AL; Taylor, ME, 2011) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Women with breast cancer often experience multiple concurrent symptoms during AI therapy." | 1.51 | Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy. ( Bender, CM; Conley, YP; Li, H; Marsland, AL; Sereika, SM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H | 1 |
| Sereika, SM | 1 |
| Marsland, AL | 1 |
| Conley, YP | 1 |
| Bender, CM | 1 |
| Liu, P | 1 |
| Yang, DQ | 1 |
| Xie, F | 1 |
| Zhou, B | 1 |
| Liu, M | 1 |
| Fusi, C | 1 |
| Materazzi, S | 1 |
| Benemei, S | 1 |
| Coppi, E | 1 |
| Trevisan, G | 1 |
| Marone, IM | 1 |
| Minocci, D | 1 |
| De Logu, F | 1 |
| Tuccinardi, T | 1 |
| Di Tommaso, MR | 1 |
| Susini, T | 1 |
| Moneti, G | 1 |
| Pieraccini, G | 1 |
| Geppetti, P | 1 |
| Nassini, R | 1 |
| Vercellini, P | 1 |
| Crosignani, PG | 1 |
| Somigliana, E | 1 |
| Berlanda, N | 1 |
| Barbara, G | 1 |
| Fedele, L | 1 |
| Terhorst, L | 1 |
| Blair-Belansky, H | 1 |
| Moore, PJ | 1 |
| Bender, C | 1 |
| Rastelli, AL | 1 |
| Taylor, ME | 1 |
| Gao, F | 1 |
| Armamento-Villareal, R | 1 |
| Jamalabadi-Majidi, S | 1 |
| Napoli, N | 1 |
| Ellis, MJ | 1 |
| Morales, L | 1 |
| Neven, P | 1 |
| Timmerman, D | 1 |
| Christiaens, MR | 1 |
| Vergote, I | 1 |
| Van Limbergen, E | 1 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Paridaens, R | 1 |
| Boccardo, F | 2 |
| Rubagotti, A | 2 |
| Battaglia, M | 1 |
| Di Tonno, P | 1 |
| Selvaggi, FP | 1 |
| Conti, G | 2 |
| Comeri, G | 1 |
| Bertaccini, A | 1 |
| Martorana, G | 1 |
| Galassi, P | 1 |
| Zattoni, F | 1 |
| Macchiarella, A | 1 |
| Siragusa, A | 1 |
| Muscas, G | 1 |
| Durand, F | 1 |
| Potenzoni, D | 2 |
| Manganelli, A | 2 |
| Ferraris, V | 1 |
| Montefiore, F | 1 |
| Saltzstein, D | 1 |
| Sieber, P | 1 |
| Morris, T | 1 |
| Gallo, J | 1 |
| Del Monaco, D | 1 |
| Thönnessen, D | 1 |
| Wenz, F | 1 |
| Winters, L | 1 |
| Habin, K | 1 |
| Gallagher, J | 1 |
2 reviews available for anastrozole and Pain
| Article | Year |
|---|---|
Medical treatment for rectovaginal endometriosis: what is the evidence?
Topics: Anastrozole; Aromatase Inhibitors; Cohort Studies; Danazol; Endometriosis; Female; Gonadotropin-Rele | 2009 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2007 |
6 trials available for anastrozole and Pain
| Article | Year |
|---|---|
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Ar | 2014 |
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2011 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormon | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormona | 2005 |
4 other studies available for anastrozole and Pain
| Article | Year |
|---|---|
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2019 |
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.
Topics: Anastrozole; Androstadienes; Animals; Aromatase Inhibitors; Behavior, Animal; Calcium; Calcium Chann | 2014 |
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Checklist; Chemotherapy, Adjuv | 2011 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; | 2005 |